Bonneterre J
Centre Oscar-Lambret, Lille, France.
Bull Cancer. 1995 Aug;82(8):623-8.
Topoisomerase I inhibitors are a new therapeutic class whose clinical evaluation began a few years ago; Irinotecan (CPT-11) gave interesting results in colon cancer; side effects were neutropenia, diarrhea, vomiting and a cholinergic syndrome. Topotecan was useful in lung and ovarian cancer; side effects were mostly hematologic. Undergoing studies concern dose optimization, mode of administration and therapeutic associations.
拓扑异构酶I抑制剂是一类新的治疗药物，其临床评估始于几年前；伊立替康（CPT-11）在结肠癌治疗中取得了令人感兴趣的结果；副作用包括中性粒细胞减少、腹泻、呕吐和胆碱能综合征。拓扑替康对肺癌和卵巢癌有效；副作用主要是血液学方面的。正在进行的研究涉及剂量优化、给药方式和联合治疗。
